See more : Indigo Star Holdings Limited (8373.HK) Income Statement Analysis – Financial Results
Complete financial analysis of Jia Jie Biomedical Co., Ltd. (4109.TWO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Jia Jie Biomedical Co., Ltd., a leading company in the Packaged Foods industry within the Consumer Defensive sector.
- KONE Oyj (KC4.DE) Income Statement Analysis – Financial Results
- CB GROUP MANAGEMENT Co., Ltd. (9852.T) Income Statement Analysis – Financial Results
- Genting Singapore Limited (GIGNF) Income Statement Analysis – Financial Results
- Banco del Bajío, S.A., Institución de Banca Múltiple (BBAJF) Income Statement Analysis – Financial Results
- SINBON Electronics Co., Ltd. (3023.TW) Income Statement Analysis – Financial Results
Jia Jie Biomedical Co., Ltd. (4109.TWO)
About Jia Jie Biomedical Co., Ltd.
Jia Jie Biomedical Co., Ltd. produces and sells health foods in Taiwan and Mainland China. The company engages in the processing, sale, and trading of softshell turtle food; manufacture of dairy products; miscellaneous food manufacturing, such as softshell turtle egg powder capsules, enzyme powder, tortoise jelly, softshell turtle oil, and powder capsules; and import and export, distribution, bidding, quotation of the products. It is also involved in the wholesale of nonalcoholic beverages, candy, baked food, supplementary food, groceries, daily commodities, and cosmetics; production of water purification equipment and related parts; life and property insurance brokerage business; development and production of aquatic product technology; and development of biological products. The company was formerly known as Murad Chia Jei Biotechnology Co., Ltd. and changed its name to Jia Jie Biomedical Co., Ltd. in June 2019. Jia Jie Biomedical Co., Ltd. was founded in 1995 and is based in Kaohsiung, Taiwan.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 332.76M | 317.72M | 242.48M | 270.29M | 343.06M |
| Cost of Revenue | 215.12M | 201.21M | 158.71M | 228.58M | 255.10M |
| Gross Profit | 117.64M | 116.51M | 83.77M | 41.71M | 87.97M |
| Gross Profit Ratio | 35.35% | 36.67% | 34.55% | 15.43% | 25.64% |
| Research & Development | 9.32M | 8.94M | 3.61M | 165.00K | 1.92M |
| General & Administrative | 61.20M | 60.61M | 45.56M | 38.77M | 0.00 |
| Selling & Marketing | 113.60M | 61.35M | 35.83M | 51.10M | 0.00 |
| SG&A | 174.79M | 121.96M | 81.39M | 89.87M | 106.75M |
| Other Expenses | 0.00 | 7.91M | 5.80M | 7.29M | 0.00 |
| Operating Expenses | 183.84M | 130.90M | 85.00M | 90.03M | 108.66M |
| Cost & Expenses | 398.96M | 332.11M | 243.71M | 318.61M | 363.76M |
| Interest Income | 1.82M | 1.21M | 480.00K | 103.00K | 298.00K |
| Interest Expense | 348.00K | 113.00K | 61.00K | 713.00K | 2.90M |
| Depreciation & Amortization | 14.89M | 16.87M | 13.44M | 15.66M | 18.23M |
| EBITDA | 161.30M | 12.12M | 18.58M | -25.50M | -4.34M |
| EBITDA Ratio | 48.47% | 3.65% | 7.63% | -9.35% | -1.26% |
| Operating Income | -66.20M | -5.28M | 5.06M | -40.93M | -20.70M |
| Operating Income Ratio | -19.89% | -1.66% | 2.08% | -15.14% | -6.03% |
| Total Other Income/Expenses | 212.75M | 9.00M | 6.22M | 6.68M | -4.77M |
| Income Before Tax | 146.55M | -4.68M | 5.29M | -41.65M | -25.46M |
| Income Before Tax Ratio | 44.04% | -1.47% | 2.18% | -15.41% | -7.42% |
| Income Tax Expense | -475.00K | 1.76M | 191.00K | -8.96M | -1.05M |
| Net Income | 144.15M | -5.47M | 5.34M | -31.93M | -24.48M |
| Net Income Ratio | 43.32% | -1.72% | 2.20% | -11.81% | -7.14% |
| EPS | 1.62 | -0.06 | 0.06 | -0.46 | -0.36 |
| EPS Diluted | 1.62 | -0.06 | 0.06 | -0.46 | -0.36 |
| Weighted Avg Shares Out | 88.94M | 88.94M | 88.94M | 69.43M | 68.94M |
| Weighted Avg Shares Out (Dil) | 89.19M | 88.94M | 88.94M | 69.43M | 68.94M |
Source: https://incomestatements.info
Category: Stock Reports